Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Dalbavancin As Suppressive Therapy

NCT06899906 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.

NCT NCT06899906
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06899906 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Dalbavancin As Suppressive Therapy
Lead sponsor
Hospices Civils de Lyon
Phase
Observational
Overall status
Recruiting
Start date
October 1, 2024
Completion date
May 1, 2025
Enrollment
33 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

efficacy and safety of dalbavancin, for acute or chronic infections between july 2019 and december 2024, in subjects who received sat with dal